Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives

References

• Allison AC. Notes on sickle-cell polymorphism. Ann Hum Genet. 1954;19(1):39–51. doi:10.1111/j.1469-1809.1954.tb01261.x
   PubMed Web of Science ®Google Scholar
• Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104. doi:10.1038/ncomms1104
   PubMed Web of Science ®Google Scholar
• Esoh K, Wonkam A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. Hum Mol Genet. 2021;30(R1):R119–R128. doi:10.1093/hmg/ddab004
   PubMed Web of Science ®Google Scholar
• Wailoo K. Drawing Blood: Technology and Disease Identity in Twentieth-Century America. Johns Hopkins University Press; 1999.
   Google Scholar
• Steinberg MH. Pathophysiology of sickle cell disease. Baillieres Clin Haematol. 1998;11(1):163–184. doi:10.1016/s0950-3536(98)80074-7
   PubMedGoogle Scholar
• Carden MA, Fasano RM, Meier ER. Not all red cells sickle the same: contributions of the reticulocyte to disease pathology in sickle cell anemia. Blood Rev. 2020;40:100637. doi:10.1016/j.blre.2019.100637
   PubMed Web of Science ®Google Scholar
• Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014;28(2):181–198. doi:10.1016/j.hoc.2013.11.005
   PubMed Web of Science ®Google Scholar
• Kuypers FA. Hemoglobin s polymerization and red cell membrane changes. Hematol Oncol Clin North Am. 2014;28(2):155–179. doi:10.1016/j.hoc.2013.12.002
   PubMed Web of Science ®Google Scholar
• Nouraie M, Lee JS, Zhang Y, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98(3):464–472. doi:10.3324/haematol.2012.068965
   PubMed Web of Science ®Google Scholar
• Liguoro I, Arigliani M, Tan HL, Gupta A. The burden of sleep disordered breathing in children with sickle cell disease. Pediatr Pulmonol. 2021;56(12):3607–3633. doi:10.1002/ppul.25632
   PubMed Web of Science ®Google Scholar
• Tantawy A, El-Sherif N, Makkeyah S, et al. Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study. Ann Hematol. 2023;102(2):271–281. doi:10.1007/s00277-023-05099-4
   PubMed Web of Science ®Google Scholar
• Vingert B, Tamagne M, Habibi A, et al. Phenotypic differences of CD4(+) T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015;45(6):1868–1879. doi:10.1002/eji.201445187
   PubMed Web of Science ®Google Scholar
• van Beers EJ, Yang Y, Raghavachari N, et al. Iron, inflammation, and early death in adults with sickle cell disease. Circ Res. 2015;116(2):298–306. doi:10.1161/CIRCRESAHA.116.304577
   PubMed Web of Science ®Google Scholar
• Hoppe CC. Inflammatory mediators of endothelial injury in sickle cell disease. Hematol Oncol Clin North Am. 2014;28(2):265–286. doi:10.1016/j.hoc.2013.11.006
   PubMed Web of Science ®Google Scholar
• Kutlar A, Embury SH. Cellular adhesion and the endothelium: p-selectin. Hematol Oncol Clin North Am. 2014;28(2):323–339. doi:10.1016/j.hoc.2013.11.007
   PubMed Web of Science ®Google Scholar
• Piccin A, Murphy C, Eakins E, et al. Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia. J Extracell Vesicles. 2015;4:28414. doi:10.3402/jev.v4.28414
   PubMed Web of Science ®Google Scholar
• Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019;102(4):319–330. doi:10.1111/ejh.13212
   PubMed Web of Science ®Google Scholar
• Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol. 2013;20(5):472–477. doi:10.1097/MOH.0b013e328363442f
   PubMed Web of Science ®Google Scholar
• Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology. 2007;2007(1):91–96. doi:10.1182/asheducation-2007.1.91
   Google Scholar
• Runge A, Brazel D, Pakbaz Z. Stroke in sickle cell disease and the promise of recent disease modifying agents. J Neurol Sci. 2022;442:120412. doi:10.1016/j.jns.2022.120412
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294.
   PubMed Web of Science ®Google Scholar
• Maduakor C, Alakbarzade V, Sammaraiee Y, et al. The epidemiology of neurological complications in adults with sickle cell disease: a retrospective cohort study. Front Neurol. 2021;12:744118. doi:10.3389/fneur.2021.744118
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–1588. doi:10.1182/bloodadvances.2019001142
   PubMed Web of Science ®Google Scholar
• Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605–610. doi:10.1056/NEJM199202273260905
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Voeks JH, Kanter J, et al. Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019;94(12):1335–1343. doi:10.1002/ajh.25635
   PubMed Web of Science ®Google Scholar
• Stotesbury H, Kawadler JM, Hales PW, Saunders DE, Clark CA, Kirkham FJ. Vascular instability and neurological morbidity in sickle cell disease: an integrative framework. Front Neurol. 2019;10:871. doi:10.3389/fneur.2019.00871
   PubMed Web of Science ®Google Scholar
• Schatz J, White DA, Moinuddin A, Armstrong M, DeBaun MR. Lesion burden and cognitive morbidity in children with sickle cell disease. J Child Neurol. 2002;17(12):890–894. doi:10.1177/08830738020170122401
   Web of Science ®Google Scholar
• Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303(18):1823–1831. doi:10.1001/jama.2010.562
   PubMed Web of Science ®Google Scholar
• Prussien KV, Jordan LC, DeBaun MR, Compas BE. Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: a meta-analysis. J Pediatr Psychol. 2019;44(8):948–958. doi:10.1093/jpepsy/jsz031
   PubMed Web of Science ®Google Scholar
• Portela GT, Butters MA, Brooks MM, Candra L, Rosano C, Novelli EM. Comprehensive assessment of cognitive function in adults with moderate and severe sickle cell disease. Am J Hematol. 2022;97(9):E344–E346. doi:10.1002/ajh.26643
   PubMed Web of Science ®Google Scholar
• Adams RJ, Nichols FT, Figueroa R, McKie V, Lott T. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke. 1992;23(8):1073–1077. doi:10.1161/01.str.23.8.1073
   PubMed Web of Science ®Google Scholar
• Siegel MJ, Luker GD, Glauser TA, DeBaun MR. Cerebral infarction in sickle cell disease: transcranial Doppler US versus neurologic examination. Radiology. 1995;197(1):191–194. doi:10.1148/radiology.197.1.7568822
   PubMed Web of Science ®Google Scholar
• Silva GS, Vicari P, Figueiredo MS, Carrete H, Idagawa MH, Massaro AR. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler findings. Stroke. 2009;40(7):2408–2412. doi:10.1161/STROKEAHA.108.537415
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19(1):110–129.
   PubMedGoogle Scholar
• Hankins JS, Fortner GL, McCarville MB, et al. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol. 2008;142(1):94–99. doi:10.1111/j.1365-2141.2008.07167.x
   PubMed Web of Science ®Google Scholar
• Jones AM, Seibert JJ, Nichols FT, et al. Comparison of transcranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sickle-cell anemia. Pediatr Radiol. 2001;31(7):461–469. doi:10.1007/s002470100427
   PubMed Web of Science ®Google Scholar
• McCarville MB, Li C, Xiong X, Wang W. Comparison of transcranial Doppler sonography with and without imaging in the evaluation of children with sickle cell anemia. Am J Roentgenol. 2004;183(4):1117–1122. doi:10.2214/ajr.183.4.1831117
   PubMed Web of Science ®Google Scholar
• Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing health care disparities in sickle cell disease: a review. Public Health Rep. 2019;134(6):599–607. doi:10.1177/0033354919881438
   PubMed Web of Science ®Google Scholar
• Wailoo K. Dying in the city of the blues: sickle cell anemia and the politics of race and health. Studies in social medicine. University of North Carolina Press; 2001. Available from: http://www.loc.gov/catdir/samples/unc041/00062865.html. Accessed April 2, 2015.
   Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. doi:10.1056/NEJM199807023390102
   PubMed Web of Science ®Google Scholar
• Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847–852. doi:10.1182/blood-2005-10-009506
   PubMed Web of Science ®Google Scholar
• Abboud MR, Yim E, Musallam KM, Adams RJ. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118(4):894–898. doi:10.1182/blood-2010-12-326298
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81(5):1109–1123.
   PubMed Web of Science ®Google Scholar
• Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr. 2009;21(1):15–21. doi:10.1097/MOP.0b013e328321882e
   PubMed Web of Science ®Google Scholar
• Marouf R. Blood transfusion in sickle cell disease. Hemoglobin. 2011;35(5–6):495–502. doi:10.3109/03630269.2011.596984
   PubMed Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355. doi:10.1182/bloodadvances.2019001143
   PubMed Web of Science ®Google Scholar
• Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016;2016(1):625–631.
   PubMedGoogle Scholar
• Talano JAM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111(6 Pt 1):e661–665.
   PubMed Web of Science ®Google Scholar
• Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol. 2009;2(2):111–115. doi:10.1586/ehm.09.2
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528–537. doi:10.1182/blood-2011-11-327361
   PubMed Web of Science ®Google Scholar
• Linder GE, Chou ST. Red cell transfusion and alloimmunization in sickle cell disease. Haematologica. 2021;106(7):1805–1815. doi:10.3324/haematol.2020.270546
   PubMed Web of Science ®Google Scholar
• LaSalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51(8):1732–1739. doi:10.1111/j.1537-2995.2010.03045.x
   PubMed Web of Science ®Google Scholar
• Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion. 2015. doi:10.1111/trf.12987
   PubMed Web of Science ®Google Scholar
• Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703–716. doi:10.1111/bjh.14575
   PubMed Web of Science ®Google Scholar
• Wilson SR, Sears M, Williams E, et al. Gaps in the diagnosis and management of iron overload in sickle cell disease: a “real-world” report from the GRNDaD registry. Br J Haematol. 2021;195(5):e157–e160. doi:10.1111/bjh.17762
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood. 2009;114(21):4632–4638. doi:10.1182/blood-2009-02-203323
   PubMed Web of Science ®Google Scholar
• Wood JC. Estimating tissue iron burden: current status and future prospects. Br J Haematol. 2015;170(1):15–28. doi:10.1111/bjh.13374
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508. doi:10.1111/j.1365-2141.2006.06455.x
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label Phase II trial. Acta Haematol. 2008;119(3):133–141. doi:10.1159/000125550
   PubMed Web of Science ®Google Scholar
• Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer. 2005;44(5):500–507. doi:10.1002/pbc.20290
   PubMed Web of Science ®Google Scholar
• Novartis. Exjade (Deferasirox). United States Food and Drug Administration; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021882s019lbl.pdf. Accessed November 21, 2022.
   Google Scholar
• Velasquez J, Wray AA. Deferoxamine. In: StatPearls. StatPearls Publishing; 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK557654/. Accessed November 21, 2022.
   Google Scholar
• Calvaruso G, Vitrano A, Di Maggio R, et al. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells Mol Dis. 2014;53(4):265–271. doi:10.1016/j.bcmd.2014.04.004
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Hamdy M, El Beshlawy A, et al. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Adv. 2022:bloodadvances.2021006778. doi:10.1182/bloodadvances.2021006778
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670. doi:10.1016/S0140-6736(15)01041-7
   PubMed Web of Science ®Google Scholar
• Treadwell MJ, Du L, Bhasin N, et al. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative. Front Genet. 2022;13:921432. doi:10.3389/fgene.2022.921432
   PubMed Web of Science ®Google Scholar
• Vick L, Potts M, Jaskowiak M, Gibson RW. Hydroxyurea adherence strategies for persons with sickle cell disease: a systematic review. J Health Care Poor Underserved. 2021;32(1):99–118. doi:10.1353/hpu.2021.0011
   PubMed Web of Science ®Google Scholar
• Hodges JR, Phillips SM, Norell S, et al. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Adv. 2020;4(18):4463–4473. doi:10.1182/bloodadvances.2020001701
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408. doi:10.1002/ajh.21699
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Duez P, Dedeken L, Cotton F, Ferster A. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2018;65(7):e27022. doi:10.1002/pbc.27022
   PubMed Web of Science ®Google Scholar
• Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022;(9). doi:10.1002/14651858.CD002202.pub3
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672. doi:10.1016/S0140-6736(11)60355-3
   PubMed Web of Science ®Google Scholar
• Lebensburger JD, Miller ST, Howard TH, et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer. 2012;59(4):675–678. doi:10.1002/pbc.24037
   PubMed Web of Science ®Google Scholar
• Smart LR, Ambrose EE, Balyorugulu G, et al. Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE): a Phase 2 primary stroke prevention trial in Sub-Saharan Africa. AHA. 2022;145(6):66. doi:10.1159/000526322
   Google Scholar
• Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. The Journal of Pediatrics. 2001;139(3):385–390. doi:10.1067/mpd.2001.117580.
   Google Scholar
• DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587–4596. doi:10.1182/blood-2011-02-272682
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699–710. doi:10.1056/NEJMoa1401731
   PubMed Web of Science ®Google Scholar
• Guilliams KP, Fields ME, Hulbert ML. Higher-than-expected prevalence of silent cerebral infarcts in children with hemoglobin SC disease. Blood. 2015;125(2):416–417. doi:10.1182/blood-2014-10-605964
   PubMed Web of Science ®Google Scholar
• Sathi BK, Yoshida Y, Weaver MR, et al. Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC Disease: a Retrospective Single Institution Study. Acta Haematol. 2022;145(2):160–169. doi:10.1159/000519360
   PubMed Web of Science ®Google Scholar
• Hasson C, Veling L, Rico J, Mhaskar R. The role of hydroxyurea to prevent silent stroke in sickle cell disease. Medicine. 2019;98(51):e18225. doi:10.1097/MD.0000000000018225
   PubMed Web of Science ®Google Scholar
• Fields ME, Guilliams KP, Ragan D, et al. Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia. Blood. 2019;133(22):2436–2444. doi:10.1182/blood-2018-09-876318
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Kimber C, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020;4:CD012389. doi:10.1002/14651858.CD012389.pub3
   PubMedGoogle Scholar
• Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461–471.
   PubMed Web of Science ®Google Scholar
• Webb J, Kwiatkowski JL. Stroke in patients with sickle cell disease. Expert Rev Hematol. 2013;6(3):301–316. doi:10.1586/ehm.13.25
   PubMed Web of Science ®Google Scholar
• Rafay MF, Shapiro KA, Surmava AM, et al. Spectrum of cerebral arteriopathies in children with arterial ischemic stroke. Neurology. 2020;94(23):e2479–e2490. doi:10.1212/WNL.0000000000009557
   PubMed Web of Science ®Google Scholar
• Aa K, Na G. How I treat and manage strokes in sickle cell disease. Blood. 2015;125(22). doi:10.1182/blood-2014-09-551564
   Web of Science ®Google Scholar
• Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr. 2006;149(5):710–712. doi:10.1016/j.jpeds.2006.06.037
   PubMed Web of Science ®Google Scholar
• Hurlet-Jensen AM, Prohovnik I, Pavlakis SG, Piomelli S. Effects of total hemoglobin and hemoglobin S concentration on cerebral blood flow during transfusion therapy to prevent stroke in sickle cell disease. Stroke. 1994;25(8):1688–1692. doi:10.1161/01.str.25.8.1688
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Lanzkron S, Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol. 2011;4(6):597–606. doi:10.1586/ehm.11.61
   PubMed Web of Science ®Google Scholar
• Frye RE. Reversible posterior leukoencephalopathy syndrome in sickle-cell anemia. Pediatr Neurol. 2009;40(4):298–301. doi:10.1016/j.pediatrneurol.2008.10.024
   PubMed Web of Science ®Google Scholar
• Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500. doi:10.1056/NEJM199602223340803
   PubMed Web of Science ®Google Scholar
• Raj S, Killinger J, Overby P. Blood transfusion in sickle cell disease leading to posterior reversible encephalopathy syndrome (PRES). J Child Neurol. 2013;28(10):1284–1286. doi:10.1177/0883073812453497
   PubMed Web of Science ®Google Scholar
• Vargas A, Testai FD. Posterior reversible encephalopathy syndrome in adult sickle-cell patients: case series and literature review. J Clin Neurosci. 2019;70:249–250. doi:10.1016/j.jocn.2019.08.070
   PubMed Web of Science ®Google Scholar
• Sidani CA, Ballourah W, El Dassouki M, et al. Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol. 2008;83(10):818–820. doi:10.1002/ajh.21261
   PubMed Web of Science ®Google Scholar
• Rahimi Z, Parsian A. Sickle cell disease and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3(1):e2011024. doi:10.4084/MJHID.2011.024
   PubMedGoogle Scholar
• Lusher JM, Haghighat H, Khalifa AS. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol. 1976;1(2):265–273. doi:10.1002/ajh.2830010210
   PubMed Web of Science ®Google Scholar
• Russell M, Goldberg H, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63(1):162–169. doi:10.1182/blood.V63.1.162.162
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896–899. doi:10.1016/S0022-3476(95)70204-0
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Kohli R, Hopewell S, Trivella M, Wang WC. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2020;7:CD003146. doi:10.1002/14651858.CD003146.pub4
   PubMedGoogle Scholar
• Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi:10.1182/blood-2011-11-392340
   PubMed Web of Science ®Google Scholar
• Kayle M, Docherty SL, Sloane R, et al. Transition to adult care in sickle cell disease: a longitudinal study of clinical characteristics and disease severity. Pediatr Blood Cancer. 2019;66(1):e27463. doi:10.1002/pbc.27463
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: u.S., 1979–2005. Public Health Rep. 2013;128(2):110–116. doi:10.1177/003335491312800206
   PubMed Web of Science ®Google Scholar
• Anie KA, Telfair J; Sickle Cell Disease Transition Study Working Group. Multi-site study of transition in adolescents with sickle cell disease in the United Kingdom and the United States. Int J Adolesc Med Health. 2005;17(2):169–178. doi:10.1515/ijamh.2005.17.2.169
   PubMedGoogle Scholar
• Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011;86(1):116–120. doi:10.1002/ajh.21880
   PubMedGoogle Scholar
• Treadwell M, Johnson S, Sisler I, et al. Development of a sickle cell disease readiness for transition assessment. Int J Adolesc Med Health. 2016;28(2):193–201. doi:10.1515/ijamh-2015-0010
   PubMedGoogle Scholar
• Currie S, Raghavan A, Batty R, Connolly DJA, Griffiths PD. Childhood moyamoya disease and moyamoya syndrome: a pictorial review. Pediatr Neurol. 2011;44(6):401–413. doi:10.1016/j.pediatrneurol.2011.02.007
   PubMed Web of Science ®Google Scholar
• Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9):3144–3150.
   PubMed Web of Science ®Google Scholar
• Griessenauer CJ, Lebensburger JD, Chua MH, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015:1–10. doi:10.3171/2014.12.PEDS14522
   Web of Science ®Google Scholar
• Winstead M, Sun PP, Martin K, et al. Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: single-institution experience. Pediatr Hematol Oncol. 2017;34(2):100–106. doi:10.1080/08880018.2017.1313917
   PubMed Web of Science ®Google Scholar
• Alamri A, Hever P, Cheserem J, Gradil C, Bassi S, Tolias CM. Encephaloduroateriosynangiosis (EDAS) in the management of Moyamoya syndrome in children with sickle cell disease. Br J Neurosurg. 2019;33(2):161–164. doi:10.1080/02688697.2017.1339227
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2016. doi:10.1182/blood-2016-10-745711
   Google Scholar
• Khemani K, Katoch D, Krishnamurti L. Curative therapies for sickle cell disease. Ochsner J. 2019;19(2):131–137. doi:10.31486/toj.18.0044
   PubMed Web of Science ®Google Scholar
• Verlhac S, Gabor F, Paillard P, et al. Improved stenosis outcome in stroke-free sickle cell anemia children after transplantation compared to chronic transfusion. Br J Haematol. 2021;193(1). doi:10.1111/bjh.17178
   PubMed Web of Science ®Google Scholar
• Thurn S, Kleinschmidt K, Kovacic I, et al. Transcranial Doppler sonography and the effect of haematopoietic stem cell transplantation in sickle cell disease. Neurol Res Pract. 2022;4(1):12. doi:10.1186/s42466-022-00175-y
   PubMedGoogle Scholar
• Wailoo K, Pemberton S. The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease. Johns Hopkins University Press; 2006. Available from: http://ebookcentral.proquest.com/lib/unc/detail.action?docID=3318266. Accessed March 18, 2022.
   Google Scholar
• DeBaun MR, Clayton EW. Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease. Blood Adv. 2017;1(26):2568–2571. doi:10.1182/bloodadvances.2017007690
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Walters MC. The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia. Blood Adv. 2017;1(26):2563–2567. doi:10.1182/bloodadvances.2017007708
   PubMed Web of Science ®Google Scholar
• Stenger E, Xiang Y, Wetzel M, et al. Long-term organ function after HCT for SCD: a report from the sickle cell transplant advocacy and research alliance. Transplant Cell Ther. 2022:S2666-6367(22)01708–0. doi:10.1016/j.jtct.2022.10.012
   Google Scholar
• Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561–2567. doi:10.1182/blood-2016-05-715870
   PubMed Web of Science ®Google Scholar
• Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020;4(16):3894–3899. doi:10.1182/bloodadvances.2020002236
   PubMed Web of Science ®Google Scholar
• Kasow KA, Krajewski J, Haines H, et al. Curing children with sickle hemoglobinopathies of varying severity early in life with HLA-matched sibling donor (MSD) hematopoietic cell transplantation (HCT) following a reduced intensity conditioning (RIC) regimen: a Sickle Transplant, Advocacy, and Research (STAR) trial. Transplant Cell Ther. 2021;29(2S):S293.
   Google Scholar
• Krishnamurti L, Neuberg DS, Sullivan KM, et al. Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study. Am J Hematol. 2019;94(4):446–454. doi:10.1002/ajh.25401
   PubMed Web of Science ®Google Scholar
• Stimpson SJ, DeBaun M. Comparing outcomes for young adults with severe SCD treated with HLA-identical sibling and matched unrelated HCT versus standard supportive care. Hematologist. 2016;13:3. doi:10.1182/hem.V13.3.5469
   Google Scholar
• Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48–56. doi:10.1001/jama.2014.7192
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016;22(3):441–448. doi:10.1016/j.bbmt.2015.08.036
   PubMed Web of Science ®Google Scholar
• Nickel RS, Chiang K, Hardy SJ, et al. Nonmyeloablative HLA-identical sibling donor transplantation for children and young adults with sickle cell disease: interim results of the SUN multicenter phase II trial. Blood. 2021;138:1799. doi:10.1182/blood-2021-144454
   Web of Science ®Google Scholar
• Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710–1719. doi:10.3324/haematol.2018.207357
   PubMed Web of Science ®Google Scholar
• Migotsky M, Beestrum M, Badawy SM. Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and L-glutamine. Pharmacy. 2022;10(5):123. doi:10.3390/pharmacy10050123
   Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. SUSTAIN: a multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of SelG1 with or without hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises. Blood. 2016;128(22):1. doi:10.1182/blood.V128.22.1.1
   PubMed Web of Science ®Google Scholar
• Safo MK, Kato GJ. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am. 2014;28(2):217–231. doi:10.1016/j.hoc.2013.11.001
   PubMed Web of Science ®Google Scholar
• Ki JH, Rc A. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8:5. doi:10.1016/S2352-3026(21)00059-4
   Google Scholar
• Hebbel RP, Hedlund BE. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am J Hematol. 2018;93(3):321–325. doi:10.1002/ajh.24975
   PubMed Web of Science ®Google Scholar
• Estepp JH, Kalpatthi R, Woods G, et al. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatr Blood Cancer. 2022;69(8):e29716. doi:10.1002/pbc.29716
   PubMed Web of Science ®Google Scholar
• Bank A, Markowitz D, Lerner N. Gene transfer. A potential approach to gene therapy for sickle cell disease. Ann N Y Acad Sci. 1989;565:37–43. doi:10.1111/j.1749-6632.1989.tb24147.x
   PubMed Web of Science ®Google Scholar
• Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021;138(11):932–941. doi:10.1182/blood.2019003776
   PubMed Web of Science ®Google Scholar
• Kolata G. Pioneering gene therapy freed her of sickle cell. Is a cure at hand? The New York Times; 2021. Available from: https://www.nytimes.com/2021/09/14/health/sickle-cell-cure.html. Accessed November 22, 2022.
   Google Scholar
• Stein R. First sickle cell patient treated with CRISPR gene-editing still thriving. NPR; 2021. Available from: https://www.npr.org/sections/health-shots/2021/12/31/1067400512/first-sickle-cell-patient-treated-with-crispr-gene-editing-still-thriving. Accessed November 22, 2022.
   Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617–628. doi:10.1056/NEJMoa2117175
   PubMed Web of Science ®Google Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386(2):138–147. doi:10.1056/NEJMoa2109167
   PubMed Web of Science ®Google Scholar
• Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer. 2003;3(7):477–488. doi:10.1038/nrc1122
   PubMed Web of Science ®Google Scholar
• Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138(11):942–947. doi:10.1182/blood.2021011488
   PubMed Web of Science ®Google Scholar